Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(2.88)
# 1,575
Out of 5,239 analysts
44
Total ratings
39.39%
Success rate
58.27%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCOY Decoy Therapeutics | Initiates: Buy | $30 | $5.15 | +482.52% | 1 | Jan 23, 2026 | |
| NXTC NextCure | Upgrades: Buy | $18 | $9.78 | +84.05% | 1 | Nov 7, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $8.83 | +69.88% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $1.64 | +1,058.54% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $18.31 | +63.84% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $4.27 | +415.22% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $6.04 | +297.35% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $15.80 | +691.14% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $1.87 | +862.57% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $1.69 | +1,024.26% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.54 | - | 1 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $79 | $215.60 | -63.28% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $21.00 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.30 | +657.58% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $4.17 | +43,065.47% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $32.94 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.85 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.64 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $2.92 | +51,269.86% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.26 | +71,328.57% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $9.62 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $18.46 | +793.82% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.07 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.54 | - | 2 | Jan 4, 2017 |
Decoy Therapeutics
Jan 23, 2026
Initiates: Buy
Price Target: $30
Current: $5.15
Upside: +482.52%
NextCure
Nov 7, 2025
Upgrades: Buy
Price Target: $18
Current: $9.78
Upside: +84.05%
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $8.83
Upside: +69.88%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $1.64
Upside: +1,058.54%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $18.31
Upside: +63.84%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $4.27
Upside: +415.22%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $6.04
Upside: +297.35%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $15.80
Upside: +691.14%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $1.87
Upside: +862.57%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $1.69
Upside: +1,024.26%
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.54
Upside: -
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $215.60
Upside: -63.28%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $21.00
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $3.30
Upside: +657.58%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $4.17
Upside: +43,065.47%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $32.94
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.85
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $3.64
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $2.92
Upside: +51,269.86%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $1.26
Upside: +71,328.57%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $9.62
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $18.46
Upside: +793.82%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $4.07
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $2.54
Upside: -